Clinical Trials Logo

Clinical Trial Summary

Autoimmune encephalitis (AE) are characterized by subacute onset of memory deficits, altered mental status or psychiatric symptoms, frequently associated with seizures, inflammatory cerebrospinal fluid and in cases with prominent limbic involvement, typical magnetic resonance imaging. Several autoantibodies (Ab) may be detected in AE, although its detection is not mandatory to establish a diagnosis. These Ab mainly recognize different synaptic and cell-surface proteins in the central nervous system, and are thought to be pathogenic as they alter the normal location or function of its antigens.

The primary trigger of the immune response is unknown for most of AE. In addition to acquired susceptibility, genetic predisposition may also be important in the pathogenesis of AE. Human leukocyte antigen (HLA) is the genetic factor most frequently associated with autoimmune diseases, due to its genetic complexity and key role in the adaptive immune response. The aim of the study is to describe HLA profile in three groups of autoimmune encephalitis and related disorders: anti-LGI1, anti-CASPR2 and anti-GAD neurological diseases.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04106596
Study type Observational
Source Hospices Civils de Lyon
Contact Jerome HONNORAT, PhD
Phone 4 72 35 78 08
Email jerome.honnorat@chu-lyon.fr
Status Not yet recruiting
Phase
Start date October 1, 2019
Completion date October 1, 2020

See also
  Status Clinical Trial Phase
Completed NCT05645185 - Characterisation of Clinical Phenotypes and Outcomes of Ma2 Patient
Completed NCT04708626 - Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden
Not yet recruiting NCT05711563 - Predicting and Monitoring Outcomes in Autoimmune Encephalitis
Completed NCT04175522 - Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis: Phase 2
Recruiting NCT03194815 - IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2 Phase 2
Not yet recruiting NCT03957616 - Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis
Completed NCT02905136 - Mechanisms of Auto-immune Encephalitis
Recruiting NCT05280600 - Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis
Recruiting NCT06173076 - A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis
Recruiting NCT03993262 - Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis Phase 2
Recruiting NCT06033846 - Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis Phase 2
Recruiting NCT04372615 - The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis Phase 2
Recruiting NCT05177939 - Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis Phase 3
Recruiting NCT06019975 - FDG-PET in the Diagnosis of Autoimmune Encephalitis
Completed NCT05783947 - Diagnostic Performance of a Commercial Assay for the Detection of Neuronal Antibodies
Completed NCT05825690 - BRIEF TITLE * (in English and Sufficiently Descriptive) Role of MRI in Anti-LGI1 Encephalitis
Not yet recruiting NCT06079294 - Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism N/A
Recruiting NCT03872284 - Neuro-ophthalmology and Autoimmune Encephalitis (NODE)
Terminated NCT03835728 - Efficacy of Ocrelizumab in Autoimmune Encephalitis Phase 2
Active, not recruiting NCT05728931 - New Biomarkers in Auto-immune Encephalitis and Neurological Paraneoplastic Syndromes